Abstract:To explore the long-term clinical effects and safety of bone marrow mononuclear cell transplantation for the treatment of cerebral infarction. Patients with cerebral infarction, hospitalized in the Second Department of Neurology at the China-Japan Friendship Hospital of Jilin University from March to November 2008, who had been diagnosed between 3 weeks and 3 months prior, and whose NIHSS score was between 5 and 30, were included in the study. Bone marrow mononuclear cells were collected the treatment group using the density gradient method. A cell suspension containing 1x10(7) bone marrow mononuclear cells was then injected into the subarachnoid space, and the outcome monitored. Neurological function, amongst other measures, were tested before transplantation, in the 3rd, 6th, 12th months of the first postoperative year, as well as in the 2nd, 3rd, 4th, 5th, 6th and 7th years after transplantation. Some mononuclear cells were amplified ex vivo; flow cytometry was used to test the markers CD90 and CD105, and immunofluorescence was used to test Nestin. Fever was observed in members of the treatment group in the initial phase after transplantation; however, this abated with time. NIH Stroke Scale scores in the 3 years after transplantation for the control and treatment groups were not significantly different (P > 0.05). In the 4th year after transplantation, the NIH Stroke Scale score of the treatment group was significantly lower than that of the control group (P < 0.05). Differences between the Barthel index, modified Rankin, and modified Functional Independence Measure scores were not significant (P > 0.05) in the 4th year after transplantation; however, they were significant in the 5th year (P < 0.05). Twelve months after transplantation, the difference between Fugl-Meyer scores was not significant (P > 0.05); however, the difference was significant (P < 0.05) in the 2nd year after transplantation. Of the mononuclear cells tested, 93.77% expressed CD90 and 60.63% expressed CD105. After ex vivo expansion, most of the bone marrow mononuclear cells were positive for Nestin. Autologous bone marrow mononuclear cell transplantation for the treatment of cerebral infarction is feasible and safe, without long-term adverse effects. It can improve neural function injury after cerebral ischemia.

Autologous Transplantation of Bone-marrow Mononuclear Cells for Treating Patients with Neurological Impairment (A Report of 5 Cases)

Autologous Transplantation of Bone-Marrow Mononuclear Cells for Treating Patients with Severe Lower Limb Ischemia (a Report of 5 Cases)

Clinical Study of Autologous Bone Marrow Nuclear Cells Transplantion Treating Motor Neuron Disease

Clinical analysis of autologous bone marrow mesenchymal stem cell transplantation for treating cerebral infarction

Study on autologous bone marrow mesenchymal stem cells on cerebral hemorrhage

Treatment of nine patients with amyotrophic lateral sclerosis by autologous peripheral blood mononuclear cells transplantation:change of short-term effect

Report of myocardial infraction treated with autologous marrow stem cell transplantation in 6 cases

Analysis Of The Long-Term Effect Of Bone Marrow Mononuclear Cell Transplantation For The Treatment Of Cerebral Infarction

Clinical efficacy and influcing factors of autologous transplantation of bone marrow mononuclear cells in the treatment of lower extremity ischemic disorders

Clinical Study of Autologous Marrow Mononuclear Cells Transplantation in Patients with Spinal Cord Injury

Prelimitary study of evaluating the stem cell therapy role in motor function improvement in neurological diseases

Transplantation of Autologous Bone Marrow Mononuclear Cells for Patients with Lower Limb Ischemia

Reinfusion of autologous bone marrow mesenchymal stem cells for treatment of stroke in 30 cases

Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury

Autologous transplantation of bone-marrow mononuclear cells for treatment of diabetic lower limb ischemia in 83 cases

A Clinical Trial Report of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation in Patients with Spinal Cord Injury.

Autologous bone marrow mononuclear cells transplantation in treatment of severe lower limb ischemia in 56 cases in the same institute: One-year follow up

Treatment of cerebral infarction using autologous marrow mesenchymal stem cells transplantation:A six-month follow-up

Clinical Study of Autologous Transplantation of Bone-Marrow Mononuclear Cells for Treating Patients with Diabetic Lower Limb Ischemia

[Middle-Term Outcome of Autologous Bone Marrow Mononuclear Cells Transplantation for Treatment of Lower Limb Ischemia].

Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients